Endothelial nanomedicine for the treatment of pulmonary disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Drug Delivery

• Publication date

  2015-01-20

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.1517/17425247.2015.961418PMID 25394760PMCID PMC8135185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Respiratory Distress Syndrome

  2016cited by this paper
• Endothelial targeting of liposomes encapsulating SOD/catalase mimetic EUK-134 alleviates acute pulmonary inflammation.

  2014cited by this paper
• Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury.

  2014cited by this paper
• The interaction between Toll-like receptor 4 signaling pathway and hypoxia-inducible factor 1α in lung ischemia-reperfusion injury.

  2014cited by this paper
• The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.

  2014cited by this paper
• Molecular Mechanisms of Pulmonary Arterial Remodeling

  2014influential reference
• Fibrinolysis for patients with intermediate-risk pulmonary embolism.

  2014cited by this paper
• Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation.

  2014cited by this paper
• Nanocarriers for vascular delivery of anti-inflammatory agents.

  2014cited by this paper
• Prevention of ventilator-induced lung edema by inhalation of nanoparticles releasing ruthenium red.

  2014cited by this paper
• A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.

  2014cited by this paper
• Barrier enhancing signals in pulmonary edema.

  2013cited by this paper
• Primary Graft Dysfunction

  2013cited by this paper
• Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.

  2013cited by this paper
• Systemic and biophase bioavailability and pharmacokinetics of nanoparticulate drug delivery systems.

  2013cited by this paper
• Anti-Inflammatory Effect of Targeted Delivery of SOD to Endothelium: Mechanism, Synergism with NO Donors and Protective Effects In Vitro and In Vivo

  2013cited by this paper
• Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study

  2013cited by this paper
• Programmable nanoparticle functionalization for in vivo targeting

  2013cited by this paper
• Vascular Immunotargeting to Endothelial Determinant ICAM-1 Enables Optimal Partnering of Recombinant scFv-Thrombomodulin Fusion with Endogenous Cofactor

  2013influential reference
• Advanced drug delivery systems for antithrombotic agents.

  2013cited by this paper
• Combination therapy in pulmonary arterial hypertension.

  2013cited by this paper
• Rodent models of group 1 pulmonary hypertension.

  2013cited by this paper
• Complement activation by PEGylated liposomes containing prednisolone.

  2013cited by this paper
• Immunotargeting of the pulmonary endothelium via angiotensin-converting-enzyme in isolated ventilated and perfused human lung.

  2013influential reference
• Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.

  2013cited by this paper
• Dysregulation of the angiopoietin–Tie-2 axis in sepsis and ARDS

  2013cited by this paper
• A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism.

  2013cited by this paper
• The Potential Efficacy of R8-Modified Paclitaxel-Loaded Liposomes on Pulmonary Arterial Hypertension

  2013cited by this paper
• VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity.

  2013cited by this paper
• Creation of Lung-Targeted Dexamethasone Immunoliposome and Its Therapeutic Effect on Bleomycin-Induced Lung Injury in Rats

  2013cited by this paper
• Pathobiology of pulmonary arterial hypertension and right ventricular failure

  2012influential reference
• Design of polymeric nanoparticles for biomedical delivery applications.

  2012cited by this paper
• A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy.

  2012cited by this paper
• A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.

  2012cited by this paper
• Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.

  2012cited by this paper
• Therapy and outcomes in massive pulmonary embolism from the Emergency Medicine Pulmonary Embolism in the Real World Registry.

  2012cited by this paper
• Models and mechanisms of acute lung injury caused by direct insults.

  2012influential reference
• Gene therapy by targeted adenovirus-mediated knockdown of pulmonary endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension.

  2012cited by this paper
• Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.

  2012cited by this paper
• Histone Deacetylation Inhibition in Pulmonary Hypertension: Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid

  2012cited by this paper
• Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

  2012cited by this paper
• Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo.

  2012cited by this paper
• Platelet-mediated vascular dysfunction during acute lung injury

  2012cited by this paper
• Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial

  2012cited by this paper
• Catalase and Superoxide Dismutase Conjugated with Platelet-Endothelial Cell Adhesion Molecule Antibody Distinctly Alleviate Abnormal Endothelial Permeability Caused by Exogenous Reactive Oxygen Species and Vascular Endothelial Growth Factor

  2011cited by this paper
• Delivery of nanoparticle‐complexed drugs across the vascular endothelial barrier via caveolae

  2011cited by this paper
• Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats

  2011cited by this paper
• Targeted gene delivery of BMPR2 attenuates pulmonary hypertension

  2011cited by this paper
• PRINT: a novel platform toward shape and size specific nanoparticle theranostics.

  2011cited by this paper
• Nanocarriers for vascular delivery of antioxidants.

  2011cited by this paper
• Endothelial targeting of antibody-decorated polymeric filomicelles.

  2011cited by this paper
• Gene therapy for pulmonary hypertension: prospects and challenges

  2011cited by this paper
• Normothermic ex vivo lung perfusion in clinical lung transplantation.

  2011cited by this paper
• Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients

  2011cited by this paper
• Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome and Acute Lung Injury in Adults and Children: A Systematic Review with Meta-Analysis and Trial Sequential Analysis

  2011cited by this paper
• HMGB1 is a therapeutic target for sterile inflammation and infection.

  2011cited by this paper
• Vascular Cell Adhesion Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen Species and Antioxidants

  2011influential reference
• PECAM‐targeted delivery of SOD inhibits endothelial inflammatory response

  2011cited by this paper
• Targeted Endothelial Delivery of Nanosized Catalase Immunoconjugates Protects Lung Grafts Donated After Cardiac Death

  2011cited by this paper
• Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury.

  2011influential reference
• Peptide-directed highly selective targeting of pulmonary arterial hypertension.

  2011cited by this paper
• The effects of polymeric nanostructure shape on drug delivery.

  2011cited by this paper
• Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation.

  2011cited by this paper
• Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity.

  2011influential reference
• Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension

  2011cited by this paper
• Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury.

  2011cited by this paper
• Liposome‐encapsulated dexamethasone attenuates ventilator‐induced lung inflammation

  2011cited by this paper
• Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs

  2010cited by this paper
• Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

  2010cited by this paper
• No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial

  2010cited by this paper
• Sterile inflammation: sensing and reacting to damage

  2010influential reference
• Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets

  2010influential reference
• Targeting the Endothelium

  2010influential reference
• Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting-enzyme antibodies.

  2010cited by this paper
• Biodesign: The process of innovating medical technologies

  2010cited by this paper
• Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

  2010cited by this paper
• Leveraging Molecular Heterogeneity of the Vascular Endothelium for Targeted Drug Delivery and Imaging

  2010cited by this paper
• Biodesign: the process of innovating medical technologies.

  2010cited by this paper
• Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase.

  2009influential reference
• Interleukin-6 Overexpression Induces Pulmonary Hypertension

  2009cited by this paper
• Targeted Detoxification of Selected Reactive Oxygen Species in the Vascular Endothelium

  2009influential reference
• Complement-Mediated Ischemia-Reperfusion Injury: Lessons Learned From Animal and Clinical Studies

  2009cited by this paper
• Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.

  2009cited by this paper
• Pivotal role of cerebral interleukin-17–producing γδT cells in the delayed phase of ischemic brain injury

  2009cited by this paper
• Nanoparticle-Mediated Delivery of Nuclear Factor &kgr;B Decoy Into Lungs Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension

  2009cited by this paper
• Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.

  2009cited by this paper
• Animal models of acute lung injury

  2008cited by this paper
• Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.

  2008cited by this paper
• Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.

  2008influential reference
• Endothelium in health and disease.

  2008cited by this paper
• Effects of Pentoxifylline on TNF-Alpha and Lung Histopathology in HCl-Induced Lung Injury

  2008cited by this paper
• Predictors of mortality from pulmonary embolism and their influence on clinical management

  2008cited by this paper
• Cicletanine for the treatment of pulmonary arterial hypertension.

  2008cited by this paper
• Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery.

  2008cited by this paper
• Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

  2008cited by this paper
• Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.

  2008influential reference
• The cancer paradigm of severe pulmonary arterial hypertension.

  2008cited by this paper
• Redox Control of Endothelial Function and Dysfunction: Molecular Mechanisms and Therapeutic Opportunities

  2008cited by this paper
• Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents.

  2008cited by this paper
• Endothelial pathomechanisms in acute lung injury

  2008cited by this paper

• Ceapin-A7 counteracts the protective effects of Lanreotide in endothelial cells

  2026cites this paper
• Nanoparticle-Based Pulmonary Immune Engineering.

  2025cites this paper
• RNA–lipid nanoparticles for acute critical illnesses

  2025cites this paper
• Application of nanotechnology and micro/nanorobots in thrombotic diseases

  2025cites this paper
• Recent strategies for enhanced delivery of mRNA to the lungs.

  2025cites this paper
• 2024 American Thoracic Society BEAR Cage Winning Proposal: Endothelial-targeted mRNA Lipid Nanoparticles for Acute Respiratory Distress Syndrome

  2025cites this paper
• Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model

  2024cites this paper
• Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy.

  2024cites this paper
• Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system

  2024cites this paper
• Hybrid biomineralized nanovesicles to enhance inflamed lung biodistribution and reduce side effect of glucocorticoid for ARDS therapy.

  2024cites this paper
• An application of pirfenidone-loaded, lung-targeted nanoliposomes for treating inflammation and early pulmonary fibrosis in ARDS

  2024cites this paper
• Pulmonary inhalation for disease treatment: Basic research and clinical translations

  2024cites this paper
• Pulmonary drug delivery for acute respiratory distress syndrome

  2023cites this paper
• Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases.

  2023cites this paper
• Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and delivery strategies.

  2023cites this paper
• Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.

  2023cites this paper
• An Externally-Applied, Natural-Mineral-Based Novel Nanomaterial IFMC Improves Cardiopulmonary Function under Aerobic Exercise

  2022cites this paper
• Exploring state-of-the-art advances in targeted nanomedicines for managing acute and chronic inflammatory lung diseases.

  2022cites this paper
• Nanocarriers for Active Ingredients of Chinese Medicine (AIFCM) Used in Gastrointestinal Cancer Therapy

  2022cites this paper
• Targeting pulmonary vascular endothelial cells for the treatment of respiratory diseases

  2022cites this paper
• The Vascular Endothelium and Coagulation: Homeostasis, Disease, and Treatment, with a Focus on the Von Willebrand Factor and Factors VIII and V

  2022cites this paper
• Expanding the arsenal against pulmonary diseases using surface-functionalized polymeric micelles: breakthroughs and bottlenecks.

  2022cites this paper
• Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

  2022cites this paper
• Emerging Approaches to Understanding Microvascular Endothelial Heterogeneity: A Roadmap for Developing Anti-Inflammatory Therapeutics

  2021cites this paper
• Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension

  2021cites this paper
• Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design

  2021cites this paper
• Mesoporous silica nanoparticles for pulmonary drug delivery.

  2021cites this paper
• Nanomedicine to advance the treatment of bacteria-induced acute lung injury.

  2021cites this paper
• Supramolecular Arrangement of Protein in Nanoparticle Structures Predicts Nanoparticle Tropism for Neutrophils in Acute Lung Inflammation

  2021cites this paper
• Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.

  2020cites this paper
• Nanoparticle Delivery Systems with Cell-specific Targeting for Pulmonary Diseases.

  2020cites this paper
• Supramolecular Organization Predicts Protein Nanoparticle Delivery to Neutrophils for Acute Lung Inflammation Diagnosis and Treatment

  2020cites this paper
• SU5416 attenuated lipopolysaccharide-induced acute lung injury in mice by modulating properties of vascular endothelial cells

  2019cites this paper
• DDDT_A_188858 1763..1772

  2019cites this paper
• Metal-organic framework (MOF) nanomedicine preparations of sildenafil designed for the future treatment of pulmonary arterial hypertension

  2019cites this paper
• Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude

  2018cites this paper
• Vascular Targeting of Radiolabeled Liposomes with Bio-Orthogonally Conjugated Ligands: Single Chain Fragments Provide Higher Specificity than Antibodies.

  2018cites this paper
• Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy

  2017cites this paper
• Site-Specific Modification of Single-Chain Antibody Fragments for Bioconjugation and Vascular Immunotargeting.

  2017cites this paper
• Inhalation therapies in acute respiratory distress syndrome.

  2017cites this paper
• Payload release by liposome burst: Thermal collapse of microgels induces satellite destruction.

  2017cites this paper
• Impact of particle elasticity on particle‐based drug delivery systems☆

  2017cites this paper
• Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome

  2017cites this paper
• Nanomedicine for the Treatment of Acute Respiratory Distress Syndrome. The 2016 ATS Bear Cage Award-winning Proposal.

  2017cites this paper
• The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series)

  2017cites this paper
• Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions.

  2017cites this paper
• Ferritin: Versatile Host, Nanoreactor, and Delivery Agent

  2016cites this paper
• Non-affinity factors modulating vascular targeting of nano- and microcarriers.

  2016cites this paper
• Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.

  2016cites this paper
• Nanotechnological applications for the control of pulmonary infections

  2016cites this paper
• Drug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systems.

  2015cites this paper
• Systems approaches to design of targeted therapeutic delivery

  2015cites this paper
• Pulmonary delivery of anti-inflammatory agents

  2015cites this paper